Chloé Rousselière

Chloé Rousselière

Auto-generated profile, based on publicly available information

Chloé Rousselière

CHU Lille, Institut de Pharmacie, F-59000 Lille, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
ECElodie Cuvelier
Elodie Cuvelier
LRLaurine Robert
Laurine Robert
EME. Musy
E. Musy
CRC. Rousselière
C. Rousselière
RMRomaric Marcilly
Romaric Marcilly
BDBertrand Décaudin
Bertrand Décaudin

24 August 2022 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
RMRomaric Marcilly
Romaric Marcilly
JCJeremie Colliaux
Jeremie Colliaux
LRLaurine Robert
Laurine Robert
SPSylvia Pelayo
Sylvia Pelayo
JBJean-Baptiste Beuscart
Jean-Baptiste Beuscart
BDBertrand Décaudin
Bertrand Décaudin

11 March 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
LRLaurine Robert
Laurine Robert
ECElodie Cuvelier
Elodie Cuvelier
CRChloé Rousselière
Chloé Rousselière
SGSophie Gautier
Sophie Gautier
POPascal Odou
Pascal Odou
BDBertrand Décaudin
Bertrand Décaudin
Clinical decision support systems (CDSSs) are intended to detect drug-related problems in real time and might be of value in healthcare institutions with a clinical pharmacy team. The objective was to report the detection of drug-related problems through a CDSS used by an existing clinical pharmacy team over 22 months. It was a retrospective single-center study. A CDSS was integrated in the clinical pharmacy team in July 2019. The investigating clinical pharmacists evaluated the pharmaceutical relevance and physician acceptance rates for critical alerts (i.e., alerts for drug-related problems arising during on-call periods) and noncritical alerts (i.e., prevention alerts arising during the pharmacist’s normal work day) from the CDSS. Of the 3612 alerts triggered, 1554 (43.0%) were critical, and 594 of these 1554 (38.2%) prompted a pharmacist intervention. Of the 2058 (57.0%) noncritical alerts, 475 of these 2058 (23.1%) prompted a pharmacist intervention. About two-thirds of the total pharmacist interventions (PI) were accepted by physicians; the proportion was 71.2% for critical alerts (i.e., 19 critical alerts per month vs. 12.5 noncritical alerts per month). Some alerts were pharmaceutically irrelevant—mainly due to poor performance by the CDSS. Our results suggest that a CDSS is a useful decision-support tool for a hospital pharmacist’s clinical practice. It can help to prioritize drug-related problems by distinguishing critical and noncritical alerts. However, building an appropriate organizational structure around the CDSS is important for correct operation.

17 March 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
FMFanny Moreau
Fanny Moreau
NSNicolas SIMON
Nicolas SIMON
JWJulia Walther
Julia Walther
MDMathilde Dambrine
Mathilde Dambrine
GKGaetan Kosmalski
Gaetan Kosmalski
POPascal Odou
Pascal Odou
The characterization of drug-drug interactions (DDIs) may require the use of several different tools, such as the thesaurus issued by our national health agency (i.e., ANSM), the metabolic pathways table from the Geneva University Hospital (GUH), and DDI-Predictor (DDI-P). We sought to (i) compare the three tools’ respective abilities to detect DDIs in routine clinical practice and (ii) measure the pharmacist intervention rate (PIR) and physician acceptance rate (PAR) associated with the use of DDI-P. The three tools’ respective DDI detection rates (in %) were measured. The PIRs and PARs were compared by using the area under the curve ratio given by DDI-P (RAUC) and applying a chi-squared test. The DDI detection rates differed significantly: 40.0%, 76.5%, and 85.2% for ANSM (The National Agency for the Safety of Medicines and Health Products), GUH and DDI-P, respectively (p < 0.0001). The PIR differed significantly according to the DDI-P’s RAUC: 90.0%, 44.2% and 75.0% for RAUC ≤ 0.5; RAUC 0.5–2 and RAUC > 2, respectively (p < 0.001). The overall PAR was 85.1% and did not appear to depend on the RAUC category (p = 0.729). Our results showed that more pharmacist interventions were issued when details of the strength of the DDI were available. The three tools can be used in a complementary manner, with a view to refining medication adjustments.

11 November 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
PQPaul Quindroit
Paul Quindroit
NBNicolas Baclet
Nicolas Baclet
EGErwin Gerard
Erwin Gerard
LRLaurine Robert
Laurine Robert
MLMadleen LEMAITRE
Madleen LEMAITRE
JBJean-Baptiste Beuscart
Jean-Baptiste Beuscart
In France, around 5% of the general population are taking drug treatments for diabetes mellitus (mainly type 2 diabetes mellitus, T2DM). Although the management of T2DM has become more complex, most of these patients are managed by their general practitioner and not a diabetologist for their antidiabetics treatments; this increases the risk of potentially inappropriate prescriptions (PIPs) of hypoglycaemic agents (HAs). Inappropriate prescribing can be assessed by approaches that are implicit (expert judgement based) or explicit (criterion based). In a mixed, multistep process, we first systematically reviewed the published definitions of PIPs for HAs in patients with T2DM. The results will be used to create the first list of explicit definitions. Next, we will complete the definitions identified in the systematic review by conducting a qualitative study with two focus groups of experts in the prescription of HAs. Lastly, a Delphi survey will then be used to build consensus among participants; the results will be validated in consensus meetings. We developed a method for determining explicit definitions of PIPs for HAs in patients with T2DM. The resulting explicit definitions could be easily integrated into computerised decision support tools for the automated detection of PIPs.

1 March 2024
Verified
Book Chapter
Open access
PDF file
SOSarah Ben Othman
Sarah Ben Othman
BDBertrand Décaudin
Bertrand Décaudin
POPascal Odou
Pascal Odou
CRChloé Rousselière
Chloé Rousselière
ECEtienne Cousein
Etienne Cousein
SHSlim Hammadi
Slim Hammadi
The health product circuit corresponds to the chain of steps that a medicine goes through in hospital, from prescription to administration. The safety and regulation of all the stages of this circuit are major issues to ensure the safety and protect the well-being of hospitalized patients. In this paper we present an automatic system for analyzing prescriptions using Artificial Intelligence (AI) and Machine Learning (ML), with the aim of ensuring patient safety by limiting the risk of prescription errors or drug iatrogeny. Our study is made in collaboration with Lille University Hospital (LUH). We exploited the MIMIC-III (Medical Information Mart for Intensive Care) a large, single-center database containing information corresponding to patients admitted to critical care units at a large tertiary care hospital.